Page of

Melanoma and immunotherapy: Melanoma and immunotherapy Expert commentary Mark Harries Expert commentary Mark Harries 

Melanoma and immunotherapy: Melanoma and immunotherapy Expert commentary Mark Harries Expert commentary Mark Harries
Chapter:
Melanoma and immunotherapy: Expert commentary Mark Harries
Source:
Challenging Concepts in Oncology
Author(s):

Sarah Ellis

DOI:
10.1093/med/9780199688883.003.0018

Melanoma is in the top five malignancies diagnosed in the UK, and its incidence is increasing. When diagnosed at an early stage, surgical excision is curative. The place of adjuvant treatment is unclear, but many trials are aiming to answer this important question. Until recently, treatment options in advanced disease were limited, with few achieving benefit from chemotherapy. The advent of immune targeted therapies and tyrosine kinase inhibitors against mutated BRAF, a driver in 50% of melanomas, has revolutionized treatment but still as yet does not offer a cure for most. The use of these drugs and the management of their toxicities is illustrated in this case. New agents against different intracellular pathways and immune targets are in development, with several offering promise. Increasing public awareness of the risk factors and early detection remain the key to reducing deaths from melanoma.

Sign In

Copyright © 2020. All rights reserved.